In Vitro Analysis of Superparamagnetic Iron Oxide Nanoparticles Coated with APTES as Possible Radiosensitizers for HNSCC Cells.
HNSCC
SPION
cell survival
doubling time
head and neck cancer cell lines
nanoparticles
time lapse
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
12 Jan 2023
12 Jan 2023
Historique:
received:
21
12
2022
revised:
05
01
2023
accepted:
09
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Superparamagnetic iron oxide nanoparticles (SPION) are being investigated for many purposes, e.g., for the amplification of ionizing radiation and for the targeted application of therapeutics. Therefore, we investigated SPIONs coated with (3-Aminopropyle)-Triethoxysilane (SPION-APTES) for their influence on different head and neck squamous cell carcinoma (HNSCC) cell lines, as well as for their suitability as a radiosensitizer. We used 24-well microscopy and immunofluorescence microscopy for cell observation, growth curves to determine cytostatic effects, and colony formation assays to determine cytotoxicity. We found that the APTES-SPIONs were very well taken up by the HNSCC cells. They generally have a low cytotoxic effect, showing no significant difference in clonogenic survival between the control group and cells treated with 20 µg Fe/mL (p > 0.25) for all cell lines. They have a cytostatic effect on some cell lines cells (e.g., Cal33) that is visible across different radiation doses (1, 2, 8 Gy, p = 0.05). In Cal33, e.g., SPION-APTES raised the doubling time at 2 Gy from 24.53 h to 41.64 h. Importantly, these findings vary notably between the cell lines. However, they do not significantly alter the radiation effect: only one out of eight cell lines treated with SPION-APTES showed a significantly reduced clonogenic survival after ionizing radiation with 2 Gy, and only two showed significantly reduced doubling times. Thus, although the APTES-SPIONs do not qualify as a radiosensitizer, we were still able to vividly demonstrate and analyze the effect that the APTES-SPIONs have on various cell lines as a contribution to further functionalization.
Identifiants
pubmed: 36678083
pii: nano13020330
doi: 10.3390/nano13020330
pmc: PMC9866044
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : AL 552/20-1, VO 2288/1-1, VO 2288/3-1, BE 5293/1-2
Références
Hum Gene Ther. 2004 Apr;15(4):351-60
pubmed: 15053860
Sci Rep. 2021 Mar 11;11(1):5674
pubmed: 33707549
Bioimpacts. 2014;4(1):15-20
pubmed: 24790894
Small. 2008 Jan;4(1):26-49
pubmed: 18165959
Strahlenther Onkol. 2022 Oct;198(10):966-969
pubmed: 35723708
J Control Release. 2022 Jun;346:98-109
pubmed: 35447296
Biochem Biophys Res Commun. 2012 Aug 24;425(2):393-7
pubmed: 22842461
Int J Mol Med. 2010 Oct;26(4):533-9
pubmed: 20818493
Iran J Pharm Res. 2019 Fall;18(4):1694-1703
pubmed: 32184839
Phys Med Biol. 2010 Jan 21;55(2):469-82
pubmed: 20023329
Biomed Rep. 2018 Nov;9(5):415-420
pubmed: 30345038
ACS Nano. 2010 Aug 24;4(8):4587-94
pubmed: 20731441
Cancers (Basel). 2022 Jan 20;14(3):
pubmed: 35158781
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8
pubmed: 18697944
J Biomed Nanotechnol. 2016 Feb;12(2):347-56
pubmed: 27305768
Nucl Med Biol. 2017 May;48:26-30
pubmed: 28189044
J Nanobiotechnology. 2015 Feb 26;13:16
pubmed: 25880445
Pharmaceutics. 2022 Oct 31;14(11):
pubmed: 36365174
J Control Release. 2022 Mar;343:288-302
pubmed: 35101477
Cancer Med. 2017 Dec;6(12):2918-2931
pubmed: 29071801
Theranostics. 2015 Jun 11;5(9):1030-44
pubmed: 26155318
Toxicol Appl Pharmacol. 2012 Jan 15;258(2):151-65
pubmed: 22178382
Science. 2006 Feb 3;311(5761):622-7
pubmed: 16456071
Int J Nanomedicine. 2012;7:3445-71
pubmed: 22848170
Adv Drug Deliv Rev. 2010 Mar 8;62(3):339-45
pubmed: 19909777
Chem Commun (Camb). 2015 Apr 4;51(26):5687-90
pubmed: 25715169
Strahlenther Onkol. 2022 Oct 13;:
pubmed: 36229655
Nanomaterials (Basel). 2021 Mar 13;11(3):
pubmed: 33805818
CA Cancer J Clin. 2016 May;66(3):203-39
pubmed: 27002678
Cancer Res Treat. 2016 Jul;48(3):907-16
pubmed: 26582394
Radiat Oncol. 2015 Nov 04;10:223
pubmed: 26537797
J Cereb Blood Flow Metab. 2010 Jan;30(1):15-35
pubmed: 19756021
Acc Chem Res. 2011 Oct 18;44(10):853-62
pubmed: 21528865
Appl Biochem Biotechnol. 2014 May;173(1):36-54
pubmed: 24615524
Acta Biomater. 2022 Mar 15;141:418-428
pubmed: 34999260
Methods Enzymol. 2020;630:39-79
pubmed: 31931995
Clin Transl Oncol. 2021 May;23(5):913-921
pubmed: 33635468
Bioengineering (Basel). 2022 Dec 15;9(12):
pubmed: 36551012
Colloids Surf B Biointerfaces. 2019 Feb 1;174:95-102
pubmed: 30445255
Nat Commun. 2022 Nov 24;13(1):7230
pubmed: 36433976
Nanotoxicology. 2020 May;14(4):504-532
pubmed: 32037933
Strahlenther Onkol. 2021 Jul;197(7):622-632
pubmed: 33245378
Photochem Photobiol Sci. 2016 Nov 30;15(12):1567-1578
pubmed: 27872929
J Phys Chem B. 2014 Jun 12;118(23):6159-66
pubmed: 24827589
Phys Med Biol. 2010 Jun 7;55(11):3045-59
pubmed: 20463371